Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19 déc. 2024 16h15 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
10 déc. 2024 18h26 HE
|
Myriad Genetics, Inc.
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10 déc. 2024 16h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
10 déc. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09 déc. 2024 16h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
09 déc. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
20 nov. 2024 16h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
19 nov. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced Prequel® Prenatal Screen is now available at
eight weeks into pregnancy.
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
13 nov. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations.
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
07 nov. 2024 16h05 HE
|
Myriad Genetics, Inc.
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third...